SG/CALL/REGENERON PHARMACEUTICALS/900/0.01/20.12.24 Share Price

Warrant

DE000SV46BH9

Market Closed - Deutsche Boerse AG 01:19:01 29/06/2024 am IST
1.81 EUR -1.09% Intraday chart for SG/CALL/REGENERON PHARMACEUTICALS/900/0.01/20.12.24
Current month+42.52%
1 month+47.15%
Date Price Change
28/24/28 1.81 -1.09%
27/24/27 1.83 -7.58%
26/24/26 1.98 -1.00%
25/24/25 2 +4.17%
24/24/24 1.92 +1.05%

Delayed Quote Deutsche Boerse AG

Last update June 29, 2024 at 01:19 am IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying REGENERON PHARMACEUTICALS, INC.
IssuerLogo Issuer Société Générale Société Générale
WKN SV46BH
ISINDE000SV46BH9
Date issued 09/05/2023
Strike 900 $
Maturity 20/12/2024 (173 Days)
Parity 100 : 1
Emission price 0.85
Emission volume N/A
Settlement Por diferencias
Currency EUR

Technical Indicators

Highest since issue 2.05
Lowest since issue 0.46
Delta0.83x
Omega 4.379
Premium4.48x
Gearing5.3x
Moneyness 1.168
Difference Strike -151 $
Difference Strike %-16.78%
Spread 0.02
Spread %1.08%
Intrinsic value 1.410

Company Profile

Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Sector
-
More about the company

Ratings for Regeneron Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Regeneron Pharmaceuticals, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,051 USD
Average target price
1,051 USD
Spread / Average Target
+0.04%
Consensus